Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CRV-101 in Healthy Adults
NCT03820414Phase 1Completed
- Sponsor
- Curevo Vaccine
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amezosvatein in herpes zoster (HZ) (5 arms), sponsored by Curevo Vaccine. Primary endpoints: Number of subjects experiencing solicited local injection site reactions, Number of subjects experiencing solicited systemic reactions and 2 more. Started Jan 2019; status: completed.
02
Drugs
amezosvatein
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03820414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820414.